๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials New York
Clinical trial register · United States · industry-sponsored

Clinical Trials in New York

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9109 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Sep 2026, 04:27 UTC
9109
Studies in scope
industry-sponsored, all four open statuses
4946
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 23 Florida 17 New York 16 Michigan 13 Texas 12
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to
16 of 9109 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers
NCT07769502Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
AbbVie
Phase 2
168
New York
2026-09-22
Recruiting
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
NCT07024615Pancreatic Ductal Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 1
25
Massachusetts, New York, North Carolina
2025-10-16
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Astellas Pharma Inc
Phase 1
364
California, Georgia, Louisiana, Michigan, Missouri, New Jersey, New York, Ohio
2025-07-25
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
Verastem, Inc.
Phase 1/2
295
California, Maryland, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Tennessee
2025-06-24
Recruiting
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06673017Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
PanTher Therapeutics
Phase 1
26
California, Florida, Michigan, New York, Texas, Washington
2025-04-14
Recruiting
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Merck Sharp & Dohme LLC
Phase 1/2
220
California, Colorado, District of Columbia, Florida, Georgia, New York, Texas, Virginia
2024-06-20
Recruiting
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT06218914Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
AstraZeneca
Phase 1
108
California, Florida, Illinois, Kansas, Massachusetts, Missouri, New York, Oregon
2024-03-22
Active, closed
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
Affini-T Therapeutics, Inc.
Phase 1/2
100
California, Connecticut, New York, Oregon, Tennessee, Texas, Washington, Wisconsin
2024-03-06
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 2
226
California, Kentucky, New York, Rhode Island, Texas
2023-12-13
Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc.
Phase 1/2
534
California, Colorado, Florida, Indiana, Massachusetts, Michigan, New York, Oklahoma
2023-11-14
Recruiting
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
NCT06084481Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma
AbbVie
Phase 1
325
California, Colorado, Florida, Illinois, Michigan, Missouri, New York, North Carolina
2023-11-09
Active, closed
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
NCT05799274Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma
Radiopharm Theranostics, Ltd
Phase 1
9
New Jersey, New York
2023-11-09
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
AstraZeneca
Phase 1/2
280
Florida, Minnesota, New York
2023-07-11
Active, closed
A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma
NCT05846516Pancreatic Ductal Adenocarcinoma
Boehringer Ingelheim
Phase 1
59
California, Colorado, Florida, Michigan, New York, Ohio, Texas, Virginia
2023-05-11
Active, closed
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
Revolution Medicines, Inc.
Phase 1
222
Arkansas, California, Florida, Maryland, Massachusetts, New York, Tennessee, Texas
2022-09-19
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Panbela Therapeutics, Inc.
Phase 2/3
600
Arkansas, California, Connecticut, District of Columbia, Michigan, Minnesota, New York, Ohio
2022-08-08
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-usa/state/new-york

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.